ICA-17043-10 Study Investigators. Improvements in Haemolysis and Indicators of Erythrocyte Survival Do Not Correlate with Acute Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase III Randomized, Placebo-Controlled, Double-Blind Study of the Gardos Channel Blocker Senicapoc (ICA-17043).